Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism

Blood

Volumn 131, Issue 19, 2018, Pages 2151-2160

  Kearon, Clive ^a,i   Parpia, Sameer ^a   Spencer, Frederick A ^a   Baglin, Trevor ^b   Stevens, Scott M ^c   Bauer, Kenneth A ^d   Lentz, Steven R ^e   Kessler, Craig M ^f   Douketis, James D ^a   Moll, Stephan ^g   Kaatz, Scott ^h   Schulman, Sam ^a   Connors, Jean M ^d   Ginsberg, Jeffrey S ^a   Spadafora, Luciana ^a   Bhagirath, Vinai ^a   Liaw, Patricia C ^a   Weitz, Jeffrey I ^a   Julian, Jim A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h HURLEY MEDICAL CENTER   (United States)

ⁱ HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; D DIMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; AUTOANTIBODY; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PHOSPHOLIPID ANTIBODY;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; THROMBOSIS; ADOLESCENT; AGED; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; IMMUNOLOGY; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; AUTOANTIBODIES; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RISK FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 85047881573     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-09-805689     Document Type: Article

References (18)

1. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11): 1033-1044.
2. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013;122(5):817-824.
3. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ. 2010;340:c2541.
4. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-1509.
5. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
6. Kearon C, Spencer FA, O’Keeffe D, et al; D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015;162(1):27-34.
7. Kearon C, Parpia S, Spencer FA, et al. D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. Thromb Res. 2016;146:119-125.
8. Neale D, Tovey C, Vali A, et al. Evaluation of the Simplify D-dimer assay as a screening test for the diagnosis of deep vein thrombosis in an emergency department. Emerg Med J. 2004;21(6):663-666.
9. Harris EN, Asherson RA, Hughes GR. Antiphospholipid antibodies–autoantibodies with a difference. Annu Rev Med. 1988;39: 261-271.
10. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost. 1993;70(5):787-793.
11. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood. 1986;68(4):869-874.
12. Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480-1483.
13. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17): 4714-4718.
14. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242.
15. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012;10(12):2512-2518.
16. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280-286.
17. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
18. Chong LY, Fenu E, Stansby G, Hodgkinson S; Guideline Development Group. Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. BMJ. 2012;344:e3979.